December 18, 2009 - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, "Chugai")] announced today that on December 18, 2009, the Ministry of Health, Labour and Welfare granted approval for the anti-influenza drug oseltamivir phosphate [product name: Tamiflu®] in an additional indication of "prophylaxis of influenza in adults, infants and children" in the formulation as Tamiflu® Dry Syrup, and it granted approval for a change in the dosage and administration for Tamiflu® Capsules in the pediatric prophylaxis indication. Chugai markets Tamiflu® in Japan.
The details can be read here.
No comments:
Post a Comment